MICHELE CREAMER: Open Payments
NPI 1740782010 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,726 in 206 payments from 22 companies in 2025. Trend: 2023 $3,889 · 2024 $3,551 · 2025 $6,726
Food & beverage: $6,726
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $811 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $679 |
| ABBVIE INC. | 17 | $624 |
| Vanda Pharmaceuticals Inc. | 14 | $606 |
| Alkermes, Inc. | 13 | $548 |
| Axsome Therapeutics, Inc. | 14 | $536 |
| Lundbeck LLC | 8 | $397 |
| Teva Pharmaceuticals USA, Inc. | 12 | $388 |
| Neurocrine BioSciences, Inc. | 16 | $382 |
| Janssen Pharmaceuticals, Inc | 2 | $244 |
Products named: REXULTI, CAPLYTA, VRAYLAR, FANAPT, INGREZZA, Auvelity, ARISTADA, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
